Craif

Craif is a biotechnology company that develops AI-powered cancer early detection technology using microRNA biomarkers from urine samples. The company has developed the NANO Intelligence Platform (NANO IP), a proprietary biomarker analysis infrastructure that analyzes diverse biosignals including DNA and RNA from body fluids, combined with advanced AI algorithms to detect cancer-specific signals at stages before symptoms appear. Craif commercializes the miSignal urine-based cancer risk test, which has been adopted by over 2,500 medical institutions in Japan through collaborations with approximately 50 university hospitals and cancer research centers. The company is also developing medical devices for pancreatic cancer early detection in both Japan and the United States, and has established its first overseas BioAI lab in San Diego at JLABS. Recent developments include detecting aging acceleration related to diabetes, hypertension, and heart disease through urinary microRNA analysis. Founded in 2018 and headquartered in Tokyo, Japan, Craif has raised approximately $39.7 million through Series C funding from investors including Toyoda Gosei, Aflac Innovation Partners, ANRI, Daiwa Corporate Investment, and Mori Trust.

Oncology > In-Vitro Diagnostic Tests > Diversified,

Genomics > Applied Genomics > Clinical Genomics > Diagnostics > Sequencing-based > Precision Medicine > Oncology

Serial Founder